Form 4: Quest Diagnostics CEO James E. Davis Reports Stock Transactions

CEO James E. Davis reports acquisition and disposition of Quest Diagnostics (DGX) common stock related to a performance share award.

Summary

• On February 23, 2024, James E. Davis, CEO and President of Quest Diagnostics, reported acquiring 13,390 shares of common stock at a price of $125.02 per share.
• This acquisition was related to the settlement of a performance share award dated February 18, 2021.
• Davis also reported disposing of 6,525 shares of common stock at $125.02 per share to cover tax withholding obligations arising from the settlement of the performance share award.
• Following these transactions, Davis beneficially owns 130,988 shares of Quest Diagnostics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are part of a standard compensation plan and tax obligations. There's no indication of unusual activity or concern.

Positives

• The acquisition of shares indicates confidence in the company's performance, as the shares were awarded based on performance metrics.

Negatives

• The disposition of shares, while for tax obligations, slightly reduces Davis's direct stake in the company.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors as they can provide insights into management's perspective on the company's stock and future prospects.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.

Key Dates